Off-label tesamorelin: body composition and the evidence
Clinical review pending
What the studies in HIV-associated lipodystrophy show about tesamorelin, and which questions remain open for other uses.
What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Under the name Egrifta, it is FDA-approved to reduce excess visceral belly fat in HIV-associated lipodystrophy. In the wellness world, it is also used in people without HIV to change body composition and for “anti-aging.” That unapproved use is the focus of this article. Source
How does tesamorelin work?
Tesamorelin binds to GHRH receptors in the pituitary gland and stimulates the body’s own release of growth hormone. This raises IGF-1. In the approved patient group, visceral fat goes down. This mechanism is well studied and forms the basis of the approved use. Whether it also translates into a benefit for other wellness goals is a separate question. Source
The prescribing information describes the growth hormone released this way as anabolic and lipolytic 1, meaning it builds tissue and breaks down fat. The HIV studies measured visceral fat specifically. The table shows how it changed in the largest study 2.
Is tesamorelin FDA-approved?
Yes, for one specific use: as Egrifta, against excess belly fat in HIV-associated lipodystrophy. The marketed products are Egrifta SV 1 and Egrifta WR 3. According to the prescribing information, the drug is not intended for general weight loss 1. The contraindications it lists include the following 1:
-
Pregnancy.
-
Active malignant tumor disease.
-
Disorders of the hypothalamic-pituitary axis.
Other uses, including general changes in body composition or “anti-aging” in people without HIV, fall outside the approval. Compounding tesamorelin for such purposes sits in a regulatory area that has not been conclusively settled. In sport, tesamorelin is prohibited at all times; WADA explicitly lists it as a prohibited GHRH analog. Source
What does the research show?
The evidence for the approved use is considerably stronger than for the wellness use extrapolated from those data. A randomized placebo-controlled trial indexed on PubMed 2, in 404 people with HIV-associated fat accumulation, found a significant reduction in visceral fat and a rise in IGF-1, with no change in glucose parameters. In a 52-week extension 4, tesamorelin was generally well tolerated. After treatment stopped, the visceral fat that had been lost came back.
The source article cites no controlled trials designed specifically for off-label use for body composition or “anti-aging” in people without HIV. This use carries results from the HIV population over to other groups. Stimulating the growth hormone axis also brings risks and monitoring questions, such as a rise in IGF-1 and possible effects on glucose metabolism. Source
Studies at a glance
| Group | Time point | Change in visceral fat |
|---|---|---|
| Tesamorelin | 6-month phase | Decrease of 10.9% |
| Placebo | 6-month phase | Decrease of 0.6% |
| Tesamorelin with continued treatment | 12 months | Decrease of about 18% |
References provided in the source article
Sources: a randomized trial of tesamorelin in HIV-associated abdominal fat accumulation (Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010, DOI: 10.1097/QAI.0b013e3181cbdaff 2 ; 52-week extension, AIDS, 2008, DOI: 10.1097/QAD.0b013e32830a5058 4 ), indexed on PubMed; FDA records for Egrifta; and the WADA Prohibited List.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.